Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients
Skarping, Ida LU
; Förnvik, Daniel
LU
; Heide-Jørgensen, Uffe
; Sartor, Hanna
LU
; Hall, Per
; Zackrisson, Sophia
LU
and Borgquist, Signe
LU
(2021)
In Cancer Causes and Control
32(3).
p.251-260
- Abstract
Purpose: Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR). Methods: A total of 495 BC patients receiving NACT in Sweden 2005–2019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (n = 295) and cohort 2 was prospectively collected (n = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and... (More)
Purpose: Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR). Methods: A total of 495 BC patients receiving NACT in Sweden 2005–2019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (n = 295) and cohort 2 was prospectively collected (n = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and accomplishing pCR post-NACT was analyzed using logistic regression models—for the whole cohort, stratified by menopausal status, and in different St. Gallen surrogate subtypes. Results: In comparison to patients with low MD (BI-RADS a), the multivariable-adjusted odds ratio (OR) of accomplishing pCR following NACT was on a descending scale: 0.62 (95% confidence interval (CI) 0.24–1.57), 0.38 (95% CI 0.14–1.02), and 0.32 (95% CI 0.09–1.08) for BI-RADS b, c, and d, respectively. For premenopausal patients selectively, the corresponding point estimates were lower, although wider CIs: 0.31 (95% CI 0.06–1.62), 0.24 (95% CI 0.04–1.27), and 0.13 (95% CI 0.02–0.88). Subgroup analyses based on BC subtypes resulted in imprecise estimates, i.e., wide CIs. Conclusions: It seemed as though patients with higher MD at baseline were less likely to reach pCR after NACT—a finding more pronounced in premenopausal women. Larger multicenter studies are needed to enable analyses and interpretation for different BC subtypes.
(Less)
- author
- Skarping, Ida
LU
; Förnvik, Daniel
LU
; Heide-Jørgensen, Uffe
; Sartor, Hanna
LU
; Hall, Per
; Zackrisson, Sophia
LU
and Borgquist, Signe
LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast cancer, Breast density, Mammography, Neoadjuvant chemotherapy
- in
- Cancer Causes and Control
- volume
- 32
- issue
- 3
- pages
- 251 - 260
- publisher
- Springer
- external identifiers
-
- pmid:33377172
- scopus:85098264396
- ISSN
- 0957-5243
- DOI
- 10.1007/s10552-020-01379-w
- language
- English
- LU publication?
- yes
- id
- ce44f99b-3747-417e-b833-a057368ff66b
- date added to LUP
- 2021-01-08 12:53:34
- date last changed
- 2025-04-18 09:49:01
@article{ce44f99b-3747-417e-b833-a057368ff66b,
abstract = {{<p>Purpose: Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR). Methods: A total of 495 BC patients receiving NACT in Sweden 2005–2019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (n = 295) and cohort 2 was prospectively collected (n = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and accomplishing pCR post-NACT was analyzed using logistic regression models—for the whole cohort, stratified by menopausal status, and in different St. Gallen surrogate subtypes. Results: In comparison to patients with low MD (BI-RADS a), the multivariable-adjusted odds ratio (OR) of accomplishing pCR following NACT was on a descending scale: 0.62 (95% confidence interval (CI) 0.24–1.57), 0.38 (95% CI 0.14–1.02), and 0.32 (95% CI 0.09–1.08) for BI-RADS b, c, and d, respectively. For premenopausal patients selectively, the corresponding point estimates were lower, although wider CIs: 0.31 (95% CI 0.06–1.62), 0.24 (95% CI 0.04–1.27), and 0.13 (95% CI 0.02–0.88). Subgroup analyses based on BC subtypes resulted in imprecise estimates, i.e., wide CIs. Conclusions: It seemed as though patients with higher MD at baseline were less likely to reach pCR after NACT—a finding more pronounced in premenopausal women. Larger multicenter studies are needed to enable analyses and interpretation for different BC subtypes.</p>}},
author = {{Skarping, Ida and Förnvik, Daniel and Heide-Jørgensen, Uffe and Sartor, Hanna and Hall, Per and Zackrisson, Sophia and Borgquist, Signe}},
issn = {{0957-5243}},
keywords = {{Breast cancer; Breast density; Mammography; Neoadjuvant chemotherapy}},
language = {{eng}},
number = {{3}},
pages = {{251--260}},
publisher = {{Springer}},
series = {{Cancer Causes and Control}},
title = {{Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients}},
url = {{http://dx.doi.org/10.1007/s10552-020-01379-w}},
doi = {{10.1007/s10552-020-01379-w}},
volume = {{32}},
year = {{2021}},
}